Teva Pharmaceuticals announced 25 presentations examining new Phase 3 clinical data, post hoc analyses and open-label extension studies for both TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) and AUSTEDO (deutetrabenazine) tablets. Study findings will be presented at the upcoming 2021 Psych Congress Annual Meeting taking place Oct. 29-Nov. 1, 2021 in San Antonio, TX (in addition to virtual participation). These data underscore Teva?s commitment to addressing the current unmet needs in managing mental illness. Combining creativity, scientific rigor and extensive knowledge on a broad range of technologies, Teva is working to not only uncover the full potential of existing medications, but to also provide new treatment options to support the management of neurological and psychiatric disorders like schizophrenia and tardive dyskinesia. Data presentations at this year?s Psych Congress evaluate the efficacy and safety profiles of investigational TV-46000, a subcutaneous risperidone injectable suspension being studied for the treatment of patients with schizophrenia. Presentations describe improvements in patient-centered outcomes, symptoms over time, as well as patient and healthcare professional choice and treatment experiences with TV-46000. Additional data that will be featured during the congress examine the physical,psychological and social impacts of TD on patients and caregivers, as well as explore the efficacy, safety and dosing patterns of long-term treatment with AUSTEDO? in patients with TD. Data to be presented include: TV-46000: De Novo: Efficacy and Safety of Subcutaneous Risperidone Injectable in Patients With Schizophrenia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study; TV-46000, a Long-Acting Subcutaneous Risperidone Injectable, Demonstrated Improved Patient-Centered Outcomes in Patients With Schizophrenia; TV-46000 Provided Continued Symptom Improvement in Patients With Schizophrenia During the Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention RISE Study; Robustness of TV-46000 Efficacy Data from RISE: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study in Patients With Schizophrenia; Behavioral-, Metabolic-, Endocrine-, and Cardiovascular-Related Adverse Events in Patients With Schizophrenia Treated With TV-46000; Efficacy and Safety of TV-46000, Subcutaneous Long-Acting Injectable Risperidone, by Injection Site: Post Hoc Analysis of the Phase 3 RISE Study; Contingency Planning and Risk Mitigation Strategies for a Schizophrenia Relapse Prevention Trial During the COVID-19 Pandemic; Annual Schizophrenia-Related Medical Resource Utilization and Costs Among Patients in the United States Utilizing Atypical Antipsychotic Agents: An Analysis of a Commercial Claims Database; Treatment Patterns Among Patients in the United States Utilizing Long-Acting Injectable Antipsychotic Agents: An Analysis of a Commercial Claims Database; Retrospective Analysis of a Commercial Claims Database for Predictors for Initiation of Atypical Long-Acting Injectable Antipsychotic Agents; Patient Preferences and Treatment Experiences With TV-46000, a Long-Acting Subcutaneous Injectable Risperidone Formulation; Health Care Professional Preferences and Treatment Experiences With TV-46000, a Long-Acting Injectable Risperidone Formulation; Determination of Flexible Dose Regimens for TV-46000, a Risperidone Extended Release Suspension for Subcutaneous Injection in Development for the Treatment of Schizophrenia; Exposure-Response Analysis to Assess the Relationships Between TV-46000 Pharmacokinetic Exposure Parameters, Prevention of Impending Relapse and Adverse Events; Network Meta-Analysis of Cohort Studies Involving Oral and Long-Acting Injectable Antipsychotic Agents: Administration Frequency and Incidence Rate of Hospitalization in Schizophrenia; Association of Oral and Long-Acting Injectable Antipsychotic Administration Frequency With Odds of Hospitalization in Schizophrenia: Network Meta-Analysis of Cohort Studies. AUSTEDO: De Novo: Long-Term Efficacy and Safety of Deutetrabenazine in Patients with Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonist Use; Effects of Long-Term Deutetrabenazine Treatment in Patients with Tardive Dyskinesia and Underlying Psychiatric or Mood Disorders; Dose Patterns for Long-Term Deutetrabenazine Treatment in Patients With Tardive Dyskinesia by Baseline Abnormal Involuntary Movement Scale Item 8 Score; Impact of Tardive Dyskinesia on Physical, Psychological, and Social Aspects of Patient Lives: A Survey of Patients and Caregivers in the United States; Caregiver Burden of Tardive Dyskinesia in the United States: A Survey of Impact on Caregiving Tasks, Psychological Well-Being, and Daily Activities; A Retrospective, Scoping Review of Unstructured Electronic Medical Record Data of Patients with Tardive Dyskinesia. Encore: Incidence of Adverse Events Associated With Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington?s Disease; Evaluation of the QTc Prolongation Risk of Deutetrabenazine; Effects of VMAT2 Inhibitors on Extracellular Levels of Dopamine, Norepinephrine, 5-HT and Histamine in the Striatum and Medial Prefrontal Cortex: A Dual-Probe Microdialysis Study in Awake Rats.